News

Eli Lilly’s obesity pill is ready to ask for global approval

Eli Lilly’s trial testing its obesity pill found that the highest dose of the drug lowered participants weight by 10.5% ...

Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals

Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the ...

Stock Movers: Eli Lilly, EchoStar, UnitedHealth

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

How the top pharma companies are doing as Eli Lilly is S&P 500’s biggest gainer

Eli Lilly and Co. (NYSE:LLY) is currently the best performer in the S&P 500 (SP500), after the pharmaceutical announced that ...

Goldman Sachs Remains Positive as Eli Lilly (LLY) Expands Obesity Drug Pipeline

Reflecting this potential, Goldman Sachs analyst Asad Haider on August 15 reiterated a Buy rating on Eli Lilly and Company ...

Stock Movers: AT&T, Eli Lilly, AMD

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Healthy Returns: Eli Lilly’s chief scientific officer breaks down the latest obesity pill data

Eli Lilly's Daniel Skovronsky talks the latest orforglipron trial, while UnitedHealth Group CEO Stephen Hemsley is moving ...
PharmaTimes21h

Anne White to retire as head of Lilly Neuroscience after three decades at company

Eli Lilly and Company has announced that Anne White, executive vice president and president of Lilly Neuroscience, will ...